Cargando…

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics

Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer epithelium, making it a promising target for molecular imaging and therapy. Recently, several studies found unexpected PSMA radiotracer uptake by thyroid tumors, including radioiodine-refractory (RAIR) cancers. PSMA expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bychkov, Andrey, Vutrapongwatana, Usanee, Tepmongkol, Supatporn, Keelawat, Somboon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507885/ https://www.ncbi.nlm.nih.gov/pubmed/28701709 http://dx.doi.org/10.1038/s41598-017-05481-z

Ejemplares similares

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
por: Lauri, Chiara, et al.
Publicado: (2022)

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
por: Bui, Vinh Ngoc, et al.
Publicado: (2023)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
por: Lütje, Susanne, et al.
Publicado: (2019)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

Current Status of Thyroid Fine-Needle Aspiration Practice in Thailand
por: Keelawat, Somboon, et al.
Publicado: (2017)

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer
por: Choden, Sonam, et al.
Publicado: (2020)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
por: Gauthé, Mathieu, et al.
Publicado: (2021)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy
por: Seifert, Robert, et al.
Publicado: (2021)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
por: Gorges, Tobias M., et al.
Publicado: (2016)

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
por: Aide, Nicolas, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
por: Ng, Thomas S. C., et al.
Publicado: (2021)

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
por: Derks, Yvonne H. W., et al.
Publicado: (2023)

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid
por: Heitkötter, Birthe, et al.
Publicado: (2018)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors
por: Gourni, Eleni, et al.
Publicado: (2015)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer
por: Derks, Yvonne H. W., et al.
Publicado: (2022)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

Nuclear imaging for localization and surgical outcome prediction in epilepsy: A review of latest discoveries and future perspectives
por: Sukprakun, Chanan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j5vru3uea971c7v00p5ipi18qg